Vorinostat Shows Anti-Cancer Activity in Recurrent Gliomas, Mayo Clinic Study Finds

CHICAGO -- North Central Cancer Treatment Group (NCCTG) researchers, based at Mayo Clinic in Rochester, Minn., report that a novel application of the drug vorinostat shows activity in patients with recurrent glioblastoma multiforme. These findings were presented today at the American Society of Clinical Oncology Annual Meeting by Eva Galanis, M.D., a Mayo Clinic oncologist and lead investigator of the study.